Navigation Links
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
Date:5/6/2010

n cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26). The National Cancer Institute estimates that in 2009, in the United States alone, there were 21,550 news cases of ovarian cancer and 14,600 related deaths.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements invol
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Contributed by Jeff Wilson, and Andrew Segal, M.D., Genitrix, LLC, ... Introduction , ... recently become a popular choice as a reporter gene. GFP can be ... and to track the expression, localization, , and ...
... Helen Chun, Milhan Telatar and Richard A. Gatti,Department ... , Introduction ... (PTT) is a method used to screen large coding , ... gene responsible , for the autosomal ...
... Gita Ohlsson and Marianne Schwartz, Department of Clinical Genetics, , ... Denmark, , ... Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency , ... 21-hydroxylase. , In addition to deletions, approximately 20 ...
Cached Biology Technology:Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 2Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 3Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 4Protein Truncation Tests Using the DCode System 2Protein Truncation Tests Using the DCode System 3Detection of Mutations in the CYP21 Gene Using the DCode System 2Detection of Mutations in the CYP21 Gene Using the DCode System 3Detection of Mutations in the CYP21 Gene Using the DCode System 4Detection of Mutations in the CYP21 Gene Using the DCode System 5
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... , July 31, 2015 The 10 th ... held by BGI from October 22-25, 2015, in Shenzhen ... The conference is celebrating its 10 th anniversary this year. ... the world,s most influential annual meetings in the ,omics, fields, ... scientific gatherings. ICG-10 focuses on recent breakthroughs ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Researchers at the Burnham Institute for Medical Research (Burnham) ... cancer therapy by showing the link between a certain ... that feed breast tumors. Like mortar between bricks in ... stick together and collectively form tissues. Cancer cells that ...
... (Burnham) have discovered a new player in the development ... sIBM is a muscle disease that affects predominantly older ... The number of people living with sIBM is unknown, ... those over the age of 50, and due to ...
... that bats significantly reduce insect abundance and damage on ... can consume roughly twice as many plant-eating insects as ... is the first to compare the ability of bats ... a natural forest ecosystem. , A previous study by ...
Cached Biology News:T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role 2T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role 3RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Smithsonian researchers show major role of bats in plant protection 2
... be superior to transfection in some applications. ... PULSin you can study lethal proteins and ... proteins in cells. Likewise, delivery of blocking ... RNA interference experiments. ,With PULSin you ...
... delivery using PULSin may be superior to ... unlike traditional transfection, with PULSin you can ... and time course of proteins in cells. ... more information than traditional RNA interference experiments. ...
... FACSVantageTM SE flow cytometry system is the ... For over 25 years, BD cell sorters ... found in leading university, pharmaceutical, and biotechnology ... meet the research demands of today, we ...
Reacti-Bind DNA Coating Solution...
Biology Products: